Last Updated: November 17, 2026

Details for Patent: RE50634

« Back to Dashboard


Which drugs does patent RE50634 protect, and when does it expire?

Patent RE50634 protects AUGTYRO and is included in one NDA.

This patent has eighty-five patent family members in thirty-six countries.

Summary for Patent: RE50634
Title:Diaryl macrocycles as modulators of protein kinases
Abstract:The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
Inventor(s):Jingrong Jean Cui, Yishan LI, Evan W. ROGERS, Dayong Zhai
Assignee: Turning Point Therapeutics Inc
Application Number:US18/147,888
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent RE50634

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol AUGTYRO repotrectinib CAPSULE;ORAL 218213-001 Nov 15, 2023 RX Yes Yes RE50634 ⤷  Start Trial Y Y ⤷  Start Trial
Bristol AUGTYRO repotrectinib CAPSULE;ORAL 218213-002 Jun 11, 2024 RX Yes Yes RE50634 ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent RE50634

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3572416 ⤷  Start Trial C20250015 Finland ⤷  Start Trial
European Patent Office 3572416 ⤷  Start Trial 301322 Netherlands ⤷  Start Trial
European Patent Office 3572416 ⤷  Start Trial CA 2025 00011 Denmark ⤷  Start Trial
European Patent Office 3572416 ⤷  Start Trial LUC00383 Luxembourg ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.